Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 10 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
Georgetown University currently has 15 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 15 pending office actions are assigned to 15 distinct examiners, ensuring that no active matters are being reviewed by the same person. This broad distribution extends to the administrative level as well, with the portfolio spanning 10 distinct art units.
The busiest examiner, OTT, PATRICK S, is responsible for 1 pending office action. Since this busiest examiner handles only 1 of the 15 pending office actions, the portfolio is decentralized. This structure means that the university's prosecution outcomes are subject to the independent review of many different individuals across 10 distinct art units. Such a wide spread reduces the impact that any single examiner's decision-making style might have on the overall success of the university's current patenting efforts in the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (7%) |
| §101 + other | 2 (14%) |
| §103 only | 1 (7%) |
| §102 only | 1 (7%) |
| §112 only | 1 (7%) |
| Double-patenting + other | 3 (21%) |
| Multi-statute (no §101) | 4 (29%) |
| No statute on record | 1 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OTT, PATRICK S | 1 | 67.9% | +23.2% |
| AGGARWAL, SAHIL CHANDER | 1 | 100.0% | +0.0% |
| GABEL, GAILENE | 1 | 75.6% | +44.8% |
| STOICA, ELLY GERALD | 1 | 66.9% | +22.5% |
| GOLDBERG, JEANINE ANNE | 1 | 45.8% | +40.8% |
| JARRELL, NOBLE E | 1 | 81.1% | +9.7% |
| PETERS, ALEC JON | 1 | 66.7% | +54.5% |
| CHONG, YONG SOO | 1 | 43.8% | +41.6% |
| BARSKY, JARED | 1 | 50.2% | +22.7% |
| TRAN, KHOA NHAT | 1 | 43.2% | +53.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18743830 | C-KIT INHIBITORS AND USES FOR TREATING AND PREVENTING INFLAMMATORY CONDITIONS | AGGARWAL, SAHIL CHANDER | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17387090 | GENERATING HYPOTHESES IN DATA SETS | RIFKIN, BEN M | 10d overdue |
| 17940142 | GENERATING AND TESTING HYPOTHESES AND UPDATING A PREDICTIVE MODEL OF PANDEMIC INFECTIONS | CHOI, DAVID | 13d |
| 18584188 | ASSAYS AND METHODS OF USE OF THOSE ASSAYS IN THE CARE AND DIAGNOSIS OF STROKE PATIENTS | GABEL, GAILENE | — |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | GOLDBERG, JEANINE ANNE | — |
| 18290252 | USE OF RAGE INHIBITORS TO TREAT CANCER-RELATED COGNITIVE DECLINE | JARRELL, NOBLE E | — |
| 18263129 | FIBROBLAST ACTIVATION PROTEIN MODULATION TO ALTER IMMUNE CELL MIGRATION AND TUMOR INFILTRATION | PETERS, ALEC JON | — |
| 17921606 | METHODS FOR ISOLATING AND CULTURING TUMOR CELLS | TRAN, KHOA NHAT | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18138058 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION | BARSKY, JARED | 89d overdue |
| 18931500 | Manganese-Nitride Based Novel Magnetic Materials | OTT, PATRICK S | 46d |
| 18584188 | ASSAYS AND METHODS OF USE OF THOSE ASSAYS IN THE CARE AND DIAGNOSIS OF STROKE PATIENTS | GABEL, GAILENE | — |
| 18436808 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES | STOICA, ELLY GERALD | — |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | GOLDBERG, JEANINE ANNE | — |
| 18263129 | FIBROBLAST ACTIVATION PROTEIN MODULATION TO ALTER IMMUNE CELL MIGRATION AND TUMOR INFILTRATION | PETERS, ALEC JON | — |
| 18260721 | USP13 INHIBITORS AND METHODS OF USE THEREOF | CHONG, YONG SOO | — |
| 17921606 | METHODS FOR ISOLATING AND CULTURING TUMOR CELLS | TRAN, KHOA NHAT | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1784 | 1 |
| 1682 | 1 |
| 1699 | 1 |
| 1641 | 1 |
| 1623 | 1 |
| 1632 | 1 |
| 1627 | 1 |
| 3684 | 1 |
| 2123 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18931500 | Manganese-Nitride Based Novel Magnetic Materials | OTT, PATRICK S | 1784 | §112 | Final Rejection | 46d | Pending | Oct 30, 2024 |
| 18743830 | C-KIT INHIBITORS AND USES FOR TREATING AND PREVENTING INFLAMMATORY CONDITIONS | AGGARWAL, SAHIL CHANDER | — | §103§112DP | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18584188 | ASSAYS AND METHODS OF USE OF THOSE ASSAYS IN THE CARE AND DIAGNOSIS OF STROKE PATIENTS | GABEL, GAILENE | — | §103§112 | Non-Final OA | — | Pending | Feb 22, 2024 |
| 18436808 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES | STOICA, ELLY GERALD | — | §112DP | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18291113 | USE OF CIRCULATING CELL-FREE METHYLATED DNA TO DETECT TISSUE DAMAGE | GOLDBERG, JEANINE ANNE | 1682 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 22, 2024 |
| 18290252 | USE OF RAGE INHIBITORS TO TREAT CANCER-RELATED COGNITIVE DECLINE | JARRELL, NOBLE E | 1699 | §103§112 | Non-Final OA | — | Pending | Nov 10, 2023 |
| 18263129 | FIBROBLAST ACTIVATION PROTEIN MODULATION TO ALTER IMMUNE CELL MIGRATION AND TUMOR INFILTRATION | PETERS, ALEC JON | 1641 | §103§112 | Non-Final OA | — | Pending | Jul 26, 2023 |
| 18260721 | USP13 INHIBITORS AND METHODS OF USE THEREOF | CHONG, YONG SOO | 1623 | §102 | Non-Final OA | — | Pending | Jul 07, 2023 |
| 18138058 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF AGE-RELATED MACULAR DEGENERATION | BARSKY, JARED | 1628 | §103 | Final Rejection | 89d overdue | Pending | Apr 22, 2023 |
| 17921606 | METHODS FOR ISOLATING AND CULTURING TUMOR CELLS | TRAN, KHOA NHAT | 1632 | §103§112 | Final Rejection | — | Pending | Oct 26, 2022 |
| 17919726 | COMBINATION THERAPY OF ARTEMISININ-RELATED COMPOUNDS AND HISTONE DEACETYLASE INHIBITORS FOR TREATMENT OF HPV-RELATED BENIGN, PREMALIGNANT, AND MALIGNANT DISEASES | REILLY, SOPHIA JANE | 1627 | §103DP | Final Rejection | 33d | Pending | Oct 18, 2022 |
| 17940142 | GENERATING AND TESTING HYPOTHESES AND UPDATING A PREDICTIVE MODEL OF PANDEMIC INFECTIONS | CHOI, DAVID | 3684 | §101 | Final Rejection | 13d | Pending | Sep 08, 2022 |
| 17659274 | TREATING NEURAL DISEASE WITH TYROSINE KINASE INHIBITORS | COPPINS, JANET L | 1628 | — | Final Rejection | 51d overdue | Pending | Apr 14, 2022 |
| 17387090 | GENERATING HYPOTHESES IN DATA SETS | RIFKIN, BEN M | 2123 | §101§112Other | Final Rejection | 10d overdue | Pending | Jul 28, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial